The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice.
Recent studies in the NOD (non-obese diabetic) mouse model of type 1 diabetes (T1D) support the notion that tyrosine kinase inhibitors have the potential for modulating disease development. However, the therapeutic effects of AG490 on the development of T1D are unknown.Female NOD mice were treated w...
Main Authors: | Abdoreza Davoodi-Semiromi, Clive H Wasserfall, Chang Qing Xia, Rhonda M Cooper-DeHoff, Martin Wabitsch, Michael Clare-Salzler, Mark Atkinson |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3351395?pdf=render |
Similar Items
-
Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490
by: Saso Luciano, et al.
Published: (2009-05-01) -
Tyrphostin AG490 reduces inflammation and fibrosis in neonatal obstructive nephropathy.
by: Mojca Gasparitsch, et al.
Published: (2019-01-01) -
Tyrosine Kinase Inhibitor Tyrphostin AG490 Inhibits Osteoclast Differentiation in Collagenase-Induced Osteoarthritis
by: V. Gyurkovska, et al.
Published: (2014-05-01) -
Tyrphostin AG17 inhibits adipocyte differentiation in vivo and in vitro
by: Alberto Camacho, et al.
Published: (2018-05-01) -
The effect of tyrphostins AG494 and AG1478 on the autocrine growth regulation of A549 and DU145 cells
by: Agnieszka Bojko, et al.
Published: (2012-07-01)